The morbidity and mortality of intestinal tumors are among the top malignant tumors, and they are major diseases that seriously threaten people’s health. The prognosis for some patients with gastrointestinal malignancies hasRead More…
Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations
Neoantigens are peptides derived from nonsynonymous mutations in human leukocyte antigens (HLAs) that are recognized by antitumor T cells. The large diversity of HLA alleles and limited clinical samples often narrow scientists’Read More…
The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients
Nowadays, immunotherapy has dramatically changed the care of cancer patients. In the case of patients with advanced melanoma, one of the most lethal cancers of human skin, the 5-year survival rate hasRead More…
Scientists Discovered the Key Molecule Triggering Cancer Metastasis
Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…
Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis
The paradigm of the adenoma-cancer sequence has typically focused on cancer cells in colorectal cancer (CRC) development that is already validated to entail heterologous interactions between altered cells and their surrounding microenvironment.Read More…
An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound
In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…
European Commission Approved Long-Acting Antibody Therapy Evusheld for the Treatment Against COVID-19
AstraZeneca recently announced that the European Commission (EC) has approved its long-acting antibody therapy Evusheld (tesaglizumab in combination with cilgravizumab, formerly AZD7442) for the treatment of adults and adolescents with severe COVID-19Read More…
Creative Biolabs Attended the 13th World Bispecific Summit as An Exhibition Partner
As multispecifics is hailed the fourth wave of drug discovery, with more clinical candidates and commercial success than ever before, the 13th World Bispecific Summit arrived at a pivotal time to deliver the holyRead More…
Pattern and Trend of Therapeutic Antibody Discovery
Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…
Alternatives to Cope with Lengthy Clinical Development Process for COVID-19
The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…